Weinvestigated in humansthe effects of adenosine triphosphate (ATP), administered by intracoronary bolus (4-16 (Llg) or intravenous infusion (25-200 Hg/kg/min), on coronary and systemic hemodynamics and electrocardiogram (ECG) variables. All patients had normal epicardial coronary arteries. The maximal coronary blood flow velocity (CBFV)was determined with intracoronary bolus of papaverine. A 12 |ig bolus of ATP (n=12) caused maximal coronary hyperemia similar to that caused by papaverine. Intracoronary boluses caused a small brief decrease in arterial pressure but no significant changes in HRor ECGvariables. Intravenous infusion ofATP at 150 |Llg/kg/min (n=15) caused a decrease in the coronary resistance index similar to that caused by papaverine, but the rate of increase in CBFVby ATPwas smaller than that caused by papaverine. No patients had a significant change in ECGvariables, but some patients (40 %) had a serious decrease in arterial pressure. These studies suggest that maximalcoronary vasodilation can be achieved safely with intracoronary ATPadministration and that intravenous infusions at 150 |0g/kg/min cause near-maximal coronary hyperemia in most patients. (Internal Medicine 37: 818-825, 1998) 
Introduction
Manystudies of the coronary circulation, for measurement of coronary flow reserve, thallium-201 scintigraphy, and echocardiography, require the use of drugs that can safely and reliably produce maximal coronary hyperemia of brief duration. An ideal coronary vasodilator for these studies would rapidly produce maximal coronary hyperemia, would be quickly reversible, and would have neither adverse effects on systemic hemodynamicsnor electrocardiographic variables.
Somedrugs are currently used for producing maximal coronary hyperemia in humans. Intracoronary boluses of papaverine are available for producing maximal coronary hyperemia ( 1) . But papaverine has some undesirable characteristics. First, the total dose that can be given is limited by its relatively slow systemic excretion (i) , therefore, intravenous infusions can not be given without systemic hypotension. Secondly, intracoronary boluses of papaverine prolong the QTinterval and can cause polymorphous ventricular tachycardia (3 , 4) . Intravenous dipyridamole produces maximal coronary hyperemia, but its prolonged effects preclude multiple measurements of coronary vasodilator reserve during the same study (4, 5) . Even though the vasodilator effects can be attenuated by methylxanthine (6) , prolonged ischemia has been reported (7, 8) . Intracoronary boluses and intravenous infusions of adenosine cause maximal coronary hyperemia quite safely and effectively (9, 10) , thus adenosine is widely used in Europe and the United States (1 1, 12).
Currently, adenosine triphosphate (ATP) is used in place of adenosine (13, 14) , however, it is not well known in human coronary circulation whether ATP can produce maximal hyperemia safely and effectively. It has been reported that, intracoronary infusion of ATPin the canine coronary circulation causes maximalhyperemia similar to adenosine (15) . On the other hand, large doses of ATPincreases the refractory period of the atrioventricular nodes and can result in heart block in humans (16) . The purpose of this study was to examine the dose-response kinetics of intracoronary and intravenous ATPadministration in humans.
Patients and Methods

Pa tients
Twelve patients (ATP intracoronary bolus) and 15 patients (ATP intravenous infusion) with normal coronary arteries undergoing coronary angiography for the diagnosis of chest pain syndromewere selected for this study. Four patients had hypercholesterolemia (serum total cholesterol values >220 mg/ dl), one patient had hypercholesterolemia with a smoking history and two patients were smokers in the ATPintracoronary bolus group. Five patients had hypercholesterolemia, and two patients had a smoking history in the ATP intravenous infusion kg/min. In one patient infusion was stopped at 150 jig/kg/min because of severe hypotension. Infusions were performed with an infusion pump (CFV 3 100, Nihon Koden, Japan). All infusions were continued for at least 2 minutes. Data werecontinuously recorded during infusions, and measurements were obtained during the last 15 seconds of the infusions.
Intracoronary papaverine. After coronary blood flow velocity returned to the basal levels, 10 mg papaverine (10 mg/4 ml 0.9% saline) was injected through the guiding catheter into the coronary ostium, and the resultant increase in coronary blood flow velocity was recorded.
Measurements of coronary blood flow velocity
The 20-MHz3Fr coronary Doppler catheter was used to measure the coronary artery blood flow velocity. The Doppler catheter then connected to a velocimeter (Model 100, Triton Technology, Inc) and audio signal was analyzed by the fast Fourier transform (FFT) method. The technique has been described elsewhere (19).
Data analysis
Intracoronary bolus studies.
The maximalchange in coronary blood flow velocity after a bolus of intracoronary ATPor papaverine was expressed as the ratio of the maximal coronary blood flow velocity (after ATPor papaverine administration) to the resting blood flow velocity (ACBFV). Asa measurement of the change in coronary vascular resistance, the coronary vascular resistance index (ACVRi) was calculated as the quotient of the [mean aortic pressure at peak flow (mmHg)/coronary blood flow velocity at peak flow (cm/sec)] and the [mean aortic pressure at resting flow/coronary blood flow velocity at resting flow].
The time course of the increase in coronary blood flow velocity after intracoronary vasodilator administration was characterized by three parameters. Tmax was defined as the time from the onset of injection until coronary blood flow velocity reached the maximal increase in velocity. T50%was defined as the time from the onset of injection until the coronary blood flow velocity returned to 50% of the maximal increase in velocity, and T10%was defined as the time from the onset of injection until flow velocity returned to within 10%of basal flow velocity.
PQ and QTc intervals were measured. QTc interval was calculated as QT///RR (sec~1/2).
Statistical analysis Data were expressed as mean± SE. Paired differences were analyzed with a Wilcoxonsigned-rank test. Linear correlation was assessed with the least-squares method.
Results
B aseline hemodynamicand electrocardiogram variable data are shown in Tables 1 and 2 .
Intracoronary ATPbolus Coronary blood flow velocity and resistance. Intracoronary boluses of ATPproduced a dose-dependent increase in coronary blood flow velocity, and in all of the patients a 16 jug bolus increased the coronary blood flow velocity to levels within 20%of the maximal CBFVproduced by intracoronary papaverine (Table 3 , Figs. 1 and 2) . After a 12 jag bolus ofATP into the left coronary artery, 10 of 12 patients (83%) developed coronary hyperemia to levels within 20% of the maximal CBFVproduced by papaverine. The correlation of the maximal change in coronary blood flow velocity after ATP or papaverine was r = 0.96 (Fig. 3) . The time to reach the maximal coronary blood flow velocity (Tmax) after ATPwas much shorter than that of papaverine. The time from the onset of injection to the time coronary blood flow velocity returned to 50%of the maximal increase in velocity and returned to within 10% of basal levels (T50% and T10%) were increased with the dose ofATP, but both parameters were much shorter than those caused by papaverine (Table 3) .
Systemic hemodynamics and electrocardiographic changes. Intracoronary boluses ofATP or papaverine produced small, brief, dose-dependent reductions in mean arterial pressure. The fall in mean arterial pressure after a 12 or 16 [ig bolus was significantly larger than that after 0.9% saline, but significantly smaller than that after papaverine (Table 3) . There wasno significant change in heart rate after any dose of ATPinjected. But intracoronary administration of papaverine caused a significant increase in heart rate ( Table 3) .
Electroca rdiographic changes.
Intracoronary bolus of ATPdid not significantly change the PR or QTc intervals on the electrocardiogram in any dosage.
Any grade of atrioventricular block was not induced.
Intracoronary boluses of papaverine did not change the PQ interval but caused significant prolongation of the QTcinterval (Table 4) . But in four patients, the coronary vascular resistance index did not decrease to within 20%of that caused by papaverine.
ACBFV during any rate of ATPinfusion was significantly smaller than that caused by papaverine. In nine of 15 patients (60%), the infusion rate of 150 |ig/kg/min increased the coronary blood flow velocity to within 20%of the maximal coronary blood flow velocity produced by papaverine. In the remaining patients, even an infusion rate of 175 or 200 jug/kg/min did not increase the coronary blood flow velocity to within 20%of that
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During lower infusion rates (75-100 (ig/kg/min), in nine of 15 patients (60%), the coronary blood flow velocity was markedly changed in a cyclic pattern (Fig. 7) .
Systemic hemodynamics. Intravenous infusions of ATPproduced a dose-dependent fall in meanarterial blood pressure and a rise in heart rate ( Table  4) . At 150 |j.g/kg/min of ATP, the mean arterial pressure fell 16+4 mmHg, and the heart rate increased by 6±2 beats/min. In six of 15 patients (40%), during 150 jag/kg/min ATP infusion, the mean arterial pressure fell more than 20%from basal arterial pressure (Table 4 ). In one patient mean arterial pressure fell from 112 to 71 mmHg. Twopatients had a mean arterial pressure fall of less than 60 mmHgduring 1 50 |ig/kg/min ATP, and another patient did so during 175 | ig/kg/min. In all patients, these changes in arterial blood pressure and heart rate returned to baseline levels within 60 seconds after the termination of ATPinfusions.
Electrocardiographic changes.
The PR and QTc intervals did not significantly change during ATP infusions (Table 4 , Fig. 8 ). One patient had more premature atrial contractions than basal state during infusion of Intracoronary bolus of ATP Vasodilation induced by ATPhas been shown to be wholly or partially endothelium dependent in several types of isolated blood vessels and in vivo microcirculation preparations (20-25). A role has been proposed for endothelium-derived relaxing factor (EDRF), thought to be nitric oxide (NO), in ATP-induced coronary dilatation (26-29). It has also been proposed that some of the vasodilation produced by ATPis due to its degradation to adenosine (25). It is unknownhowmuchof the vasodilation caused by ATPis endothelium-dependent in human coronary resistance vessels.
Intravenous infusion ofATP It has been known that an injection of ATPis virtually all removed by a single passage through the lung (30). It has been reported that the half-life of ATPin the perfused lung is 0.2 second or less (12). Here, when ATPwas intravenously administered, ATPmight have been metabolized in the pulmonary circulation, and much of the vasodilation produced by the intravenous infusion of ATPmight have been due to its degeneration to ADP,AMP,or adenosine. We observed that, in 80% of patients, coronary blood flow velocity rose and fell in a cyclic pattern at lower intravenous infusion rates than that required to produce maximalhyperemia.
Wilson et al (9) reported that intravenous adenosine infusion rates just less than that required to produce a maximal fall in coronary resistance frequently cause a characteristic pattern of widely fluctuating coronary resistance. The clinical importance of this phenomenonis that low doses of intravenous ATPmay not cause a sustained submaximal coronary hyperemia and may not produce significant flow inhomogenity between ischemic and non-ischemic areas. A recent study demonstrated that significant dipyridamole-induced flow inhomogenity causes a per fusion defect on thallium-201 imaging (31). If low dose intravenous ATPis used for producing coronary hyperemia in thallium scintigraphy, this cyclical change of hyperemia may result in a false-negative finding. However, here all patients achieved sustained coronary hyperemia during ATPinfusion of more than 150 jug/kg/min. These data suggest that an infusion rate of 150 jig/kg/min should be used for producing coronary hyperemia in thallium scintigraphy.
Potential use ofATP The advantages ofATPover papaverine or dipyridamole are its very short duration of action, the absence of QT interval prolongation on electrocardiogram, and its efficacy that can be given by intracoronary or intravenous routes.
The potential clinical use of ATPis in the measurement of coronary flow reserve in catheterization.
Intracoronary papaverine is most commonlyused to measure coronary flow reserve. But papaverine prolongs the QT interval and can cause polymorphous ventricular tachycardia (1, 4) . In patients with impaired cardiac function like certain cardiomyopathyor old myocardial infarction, polymorphic ventricular tachycardia may be fatal arrhythmia. Intracoronary ATPmay be more advantageous than papaverine because it has no important effects on electrocardiogram. In some patients, arterial pressure fell during intravenous infusion rates causing submaximal coronary vasodilation. The peak reactive hyperemia coronary flow velocity decreased linearly following the fall in arterial pressure (17, 32, 33) . If the arterial pressure falls from the basal state in measuring coronary flow reserve, it would be possible to underestimate coronary flow reserve. So it is not favorable to measure coronary flow reserve by intravenous infusions of ATP.
Another potential clinical use of ATPis in providing coronary vasodilation in thallium scintigraphic study or echocardiographic study (34) (35) (36) (37) . The short half-life of ATP compared with that of dipyridamole maylessen the risk of prolonged coronary ischemia due to coronary steal and reduce the time required for redistribution of the isotope. This study demonstrated that 150 ]ig/kg/min of ATPinfusion caused submaximal coronary hyperemia in 73% of patients. Wethink the optimal dose of ATPgiven by intravenous route is 150 jLig/ kg/min. Further clinical studies will be needed to define the competitive sensitivity of thallium scintigraphy obtained using ATP or dipyridamole.
